TCR stimulation-mediated NFAT2 autoregulation is required for Tfh cell maintenance and survival. (A) Percentages and numbers of PSGL1hiLy6chi, PSGL1loLy6clo, and PSGL1loLyc6loPD1+CXCR5+ CD4+ T cells after day 8 LCMV infection with vehicle or CsA treatment. (B) Percentages of IFNγ+, IL-21+IFNγ+, and IL-21+ CD4+ T cells within each CD4+ T cell subset. (C) Percentages and numbers of PSGL1hiLy6chi, PSGL1loLy6clo, and PSGL1loLyc6loPD1+CXCR5+ CD4+ T cells after day 4 LCMV infection with vehicle or CsA treatment. (D) MFI of NFAT2 after day 4 LCMV infection in the indicated cell subsets. Data were analyzed with two-way ANOVA. (E) Percentages of PSGL1hiLy6chi, PSGL1loLy6clo, and PSGL1loLyc6loPD1+CXCR5+ CD4+ T cells for each indicated condition. (F) MFI of NFAT2, NFAT1, Tox or Bcl6 in PSGL1loLyc6loPD1+CXCR5+ CD4+ T cells. One-way ANOVA was used to analyze E and F. Results are representative of three independent experiments with three to five mice per experimental group. See also Fig. S4. **** = P ≤ 0.0001, *** = P ≤ 0.001, ** = P ≤ 0.01, * = P ≤ 0.05, and ns P > 0.05.